SynCo Bio Partners extends collaboration with Versartis

SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis' lead product VRS-859 (exenatide-XTEN).

Antares Pharma Announces Positive Top Line Results From Its Pivotal Phase 3 Study of Anturol Gel for the Treatment of ...

EWING, N.J.----Antares Pharma, Inc. announced today positive results from its Phase 3 study of AnturolTM Gel in patients with overactive bladder . The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied .

Researchers develop first model of hormone-induced human prostate cancer initiation and progression

Progress toward understanding the role of sex hormones in the growth of prostate cancerthe most common cancer in U.S. menhas been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.